Key result
A global active drug safety monitoring project demonstrated feasibility by successfully enrolling 309 patients with drug-resistant tuberculosis treated with bedaquiline and/or delamanid across 41 centers in 27 countries.
Why the study?
Comprehensive active TB drug safety surveillance is difficult to implement globally, motivating a study to assess the feasibility of national registers and describe adverse events from new anti-TB regimens.
Observational (n=309)
Yes
The study demonstrates the global feasibility of implementing active drug safety monitoring for new drug-resistant tuberculosis regimens across 27 countries.
Answers are grounded in this paper and cite their sources.
Supports multinational safety monitoring for drug-resistant TB therapies; leaves open questions on data quality, scalability, and clinical impact.
The World Health Organization launched a global initiative, known as aDSM (active TB drug safety monitoring and management) to better describe the safety profile of new treatment regimens for drug-resistant tuberculosis (TB) in real-world settings. However, comprehensive surveillance is difficult to implement in several countries. The aim of the aDSM project is to demonstrate the feasibility of implementing national aDSM registers and to describe the type and the frequency of adverse events (AEs) associated with exposure to the new anti-TB drugs. Following a pilot study carried out in 2016, official involvement of TB reference centres/countries into the project was sought and cases treated with bedaquiline- and/or delamanid-containing regimens were consecutively recruited. AEs were prospectively collected ensuring potential attribution of the AE to a specific drug based on its known safety profile. A total of 309 cases were fully reported from 41 centres in 27 countries (65% males; 268 treated with bedaquiline, 20 with delamanid, and 21 with both drugs) out of an estimated 781 cases the participating countries had committed to report by the first quarter of 2019.
No takes yet. Share an insight, caveat, or question.
Akkerman et al. (2019) conducted an observational in Drug-resistant tuberculosis (n=309). Bedaquiline and/or delamanid was evaluated on Feasibility of implementing national active drug safety monitoring (aDSM) registers (number of cases fully reported). A global active drug safety monitoring project demonstrated feasibility by successfully enrolling 309 patients with drug-resistant tuberculosis treated with bedaquiline and/or delamanid across 41 centers in 27 countries.
Synapse has enriched 10 related papers. Consider them for comparative context: